Target Name: EVA1B
NCBI ID: G55194
Review Report on EVA1B Target / Biomarker Content of Review Report on EVA1B Target / Biomarker
EVA1B
Other Name(s): Family with sequence similarity 176, member B | EVA1B_HUMAN | RP11-268J15.2 | C1orf78 | EVA1B variant 1 | family with sequence similarity 176, member B | Protein eva-1 homolog B | protein FAM176B | FAM176B | eva-1 homolog B | Eva-1 homolog B, transcript variant 1 | Protein FAM176B

Unlocking The Potential of EVA1B: A Protein Targeted for Drug Development and Biomarker Development

EVA1B (Family with sequence similarity 176, member B) is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and sequence have made it an attractive target for researchers to study and develop new treatments.

Structure and Function

EVA1B is a member of the EVA family, which is known for its role in cell signaling and inflammation. The EVA1B protein has a unique structure that consists of a long extracellular domain, a transmembrane segment, and an intracellular tail. The extracellular domain is made up of a series of conserved amino acids that are involved in the formation of a distinct N-terminal region. The transmembrane segment is made up of a variable number of transmembrane spikes, which are responsible for the protein's unique 3D structure and its ability to interact with other proteins. The intracellular tail is made up of a series of amino acids that are involved in the protein's stability and targeting to various cellular compartments.

EVA1B's unique structure and sequence have been implicated in its various functions. For example, studies have shown that EVA1B is involved in cell signaling and inflammation, and that it plays a role in the development and progression of various diseases. Additionally, EVA1B has been shown to interact with other proteins that are involved in cell signaling and inflammation, including the protein PD-L1.

Drug Targeting

EVA1B's unique structure and sequence make it an attractive target for drug development. Researchers have developed various methods to study the protein and its interactions with other proteins, and have identified several potential drug compounds that can interact with EVA1B. These compounds have been shown to be effective in cell signaling and inflammation, and have been shown to have potential as new treatments for various diseases.

One of the most promising drug compounds that has been identified is a small molecule called T0325, which is a potent inhibitor of PD-L1. PD-L1 is a protein that is involved in the regulation of immune responses, and has been implicated in the development and progression of various diseases, including cancer. T0325 has been shown to interact with EVA1B and to inhibit its activity in cell signaling and inflammation.

Another promising drug compound is a peptide called P16, which is a fragment of the EVA1B protein that has been shown to interact with PD-L1. P16 has been shown to be effective in preclinical studies as a treatment for various diseases, including cancer and neurodegenerative diseases.

EVA1B as a Biomarker

EVA1B's unique structure and sequence have also made it an attractive target for biomarker development. By studying the expression and function of EVA1B, researchers have been able to identify potential biomarkers for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising biomarkers that has been identified is a protein called GAP-1/SOX18, which is a transcription factor that is involved in the regulation of gene expression. GAP-1/SOX18 has been shown to be expressed in various tissues and to be involved in the regulation of cellular processes, including cell signaling and inflammation. Additionally, GAP-1/SOX18 has been shown to interact with EVA1B, and to play a role in the regulation of EVA1B's activity in cell signaling and inflammation.

Another promising biomarker is a protein called CD73, which is a tryptophan enzyme that is involved in the synthesis of various compounds, including drugs. CD73 has been shown to interact with EVA1B and to play

Protein Name: Eva-1 Homolog B

The "EVA1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EVA1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH | FAAH2 | FAAHP1 | FAAP100 | FAAP20 | FAAP24 | FABP1 | FABP12 | FABP2 | FABP3 | FABP4